Tyra Biosciences Names Dr. Doug Warner Chief Medical Officer
Tyra Biosciences, Inc. (NASDAQ: TYRA), a clinical-stage biotechnology company, has appointed Dr. Doug Warner, M.D., as Chief Medical Officer. Dr. Warner brings more than two decades of hands-on clinical development leadership, with a record of guiding global programs and helping secure approvals for innovative therapies in oncology and skeletal disease.
What Dr. Warner Will Lead at TYRA
In this role, Dr. Warner will oversee Tyra’s clinical portfolio and serve on the executive leadership team. His remit includes advancing three lead oncology candidates and supporting a planned Investigational New Drug (IND) filing for an achondroplasia program. TYRA’s CEO, Todd Harris, noted that Dr. Warner’s experience—spanning early program development through global registrations—matches the company’s needs and is especially important now as TYRA works to broaden the reach of its precision medicines.
Focused Progress with Precision Medicines
Dr. Warner shared his enthusiasm for joining Tyra Biosciences, pointing to the chance to move a home-grown pipeline forward in areas where better options are still needed: oncology and skeletal dysplasias. He underscored his commitment to the development strategies for TYRA-300, TYRA-200, and TYRA-430, with the aim of improving clinical outcomes and, ultimately, patients’ lives.
Dr. Warner’s Track Record
Before joining Tyra, Dr. Warner spent 18 years at Amgen, where he guided clinical development across a wide spectrum of oncology and bone disease programs. He served as Executive Director and Group Product Area Lead, managing teams and programs across multiple phases of development. His work contributed to well-known medicines such as Vectibix®, XGEVA®, and Prolia®. Most recently, he was Chief Medical Officer at eFFECTOR Therapeutics, where he led the clinical pipeline and oversaw key trials.
Education and Contributions
Dr. Warner earned a B.A. from the University of Pennsylvania, an M.D. from the Duke University School of Medicine, and an M.B.A. from the UCLA Anderson School of Management. His research and clinical insights have appeared in peer-reviewed journals, including The Lancet and The Journal of Clinical Oncology.
About Tyra Biosciences
Based in Carlsbad, CA, Tyra Biosciences develops next-generation precision medicines in FGFR (Fibroblast Growth Factor Receptor) biology. The company’s SNÅP platform is built to accelerate drug design and anticipate genetic alterations that can drive resistance to current therapies. With a focus on targeted oncology and genetically defined conditions, TYRA applies an accelerated small-molecule discovery engine to pursue therapies designed to make a measurable difference for patients.
Frequently Asked Questions
What will Dr. Doug Warner do as Chief Medical Officer?
He’ll lead TYRA’s clinical portfolio and help guide the company’s precision medicine programs as part of the executive team.
How much experience does Dr. Warner bring?
Dr. Warner has over 20 years in clinical development, with a history of running global programs and contributing to approvals in oncology and skeletal disease.
Which programs fall under Dr. Warner’s oversight?
He’s focused on development strategies for TYRA-300, TYRA-200, and TYRA-430, and will support a planned IND filing for an achondroplasia program.
What scientific area does Tyra prioritize?
Tyra concentrates on FGFR biology, using its SNÅP platform to speed drug design and anticipate genetic resistance to existing treatments.
Where is Tyra Biosciences headquartered?
The company is based in Carlsbad, California, with programs centered on targeted oncology and genetically defined conditions.
